Skip to main content

Table 3 Cox models of predictors for survival results

From: Pretreatment prognostic factors of survival and late toxicities for patients with nasopharyngeal carcinoma treated by simultaneous integrated boost intensity-modulated radiotherapy

Variables

Univariate

Multivariate

HR

95% CI

p

HR

95% CI

p

LRRFS

 T classificationa (T1–2 vs T3–4)

2.4

1.1–5.7

0.039

1.4

0.6–3.5

0.490

 N classificationa (N0–1 vs N2–3)

7.1

2.1–24.2

0.002

5.9

1.6–21.9

0.009

 Gross tumor volume (continuous)

1.008

1.004–1.013

< 0.001

1.005

1.001–1.010

0.013

 Lymphocyte, % (continuous)

0.956

0.916–0.999

0.045

0.971

0.926–1.019

0.235

 Monocyte, % (continuous)

1.322

1.073–1.629

0.009

1.210

0.997–1.041

0.061

DMFS

 Gender (Male vs Female)

0.2

0.1–0.9

0.041

0.2

0.1–1.2

0.076

 N classificationa (N0–1 vs N2–3)

3.8

1.4–10.3

0.009

3.7

1.3–9.8

0.012

 Gross tumor volume (continuous)

1.006

1.002–1.011

0.005

1.003

0.998–1.008

0.223

FFS

 Gender (Male vs Female)

0.3

0.1–0.8

0.016

0.4

0.1–1.2

0.104

 T classificationa (T1–2 vs T3–4)

1.9

1.0–3.5

0.048

1.4

0.7–2.7

0.369

 N classificationa (N0–1 vs N2–3)

4.0

1.9–8.5

< 0.001

3.9

1.6–9.0

0.001

 Gross tumor volume (continuous)

1.007

1.004–1.010

< 0.001

1.002

0.998–1.006

0.270

 EBV DNA (<  1500 vs ≥ 1500 copies/ml)

3.7

1.1–9.2

0.031

1.2

0.3–3.6

0.536

 Monocyte, % (continuous)

1.255

1.072–1.470

0.005

1.261

1.057–1.503

0.010

OS

 Age (continuous)

1.028

1.000–1.059

0.044

1.041

1.001–1.082

0.046

 Educational level (≤ 12 vs > 12 year)

0.3

0.1–0.9

0.040

0.4

0.1–1.9

0.259

 Charlson Comorbidity Index (0 vs ≥ 1)

2.0

1.0–4.0

0.043

2.3

0.9–6.2

0.098

 T classificationa (T1–2 vs T3–4)

2.5

1.3–5.0

0.008

2.3

0.9–6.0

0.100

 N classificationa (N0–1 vs N2–3)

3.8

1.7–8.3

< 0.001

7.3

1.8–29.0

0.005

 Gross tumor volume (continuous)

1.007

1.004–1.011

0.001

1.002

0.995–1.008

0.639

 EBV DNA (<  1500 vs ≥ 1500 copies/ml)

4.2

1.8–10.0

0.001

1.5

0.5–4.3

0.426

 L/M ratio (continuous)

0.788

0.649–0.957

0.018

0.676

0.488–0.936

0.018

  1. LRRFS locoregional relapse-free survival, DMFS distant metastasis-free survival, FFS failure-free survival, OS overall survival, L/M ratio lymphocyte-to-monocyte ratio, EBV Epstein-Barr virus, HR hazard ratio, CI confidence interval
  2. aAccording to the AJCC 7th staging system